Wu Wenbin, You Keyou, Zhong Jinchan, Ruan Zhanwei, Wang Bubu
Department of Laboratory Medicine, the Third Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
Department of Pediatrics, the Third Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
J Int Med Res. 2019 Sep;47(9):4051-4058. doi: 10.1177/0300060519862057. Epub 2019 Aug 7.
The present study aimed to elucidate the underlying pathogenesis of Kawasaki disease (KD) and to identify potential biomarkers for KD.
Gene expression profiles for the GSE68004 dataset were downloaded from the Gene Expression Omnibus database. The pathways and functional annotations of differentially expressed genes (DEGs) in KD were examined by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool. Protein–protein interactions of the above-described DEGs were investigated using the Search Tool for the Retrieval of Interacting Genes (STRING).
Gene Ontology analysis revealed that DEGs in KD were significantly enriched in biological processes, including the inflammatory response, innate immune response, defense response to Gram-positive bacteria, and antibacterial humoral response. In addition, 10 hub genes with high connectivity were selected from among these DEGs (, , , , , , , , , and
The identification of several novel hub genes in KD enhances our understanding of the molecular mechanisms underlying the progression of this disease. These genes may be potential diagnostic biomarkers and/or therapeutic molecular targets in patients with KD. ITGAM inhibitors in particular may be potential targets for KD therapy.
本研究旨在阐明川崎病(KD)的潜在发病机制,并确定KD的潜在生物标志物。
从基因表达综合数据库下载GSE68004数据集的基因表达谱。使用注释、可视化和综合发现数据库(DAVID)工具,通过基因本体论和京都基因与基因组百科全书通路富集分析,研究KD中差异表达基因(DEG)的通路和功能注释。使用相互作用基因检索工具(STRING)研究上述DEG的蛋白质-蛋白质相互作用。
基因本体论分析显示,KD中的DEG在生物过程中显著富集,包括炎症反应、先天免疫反应、对革兰氏阳性菌的防御反应和抗菌体液反应。此外,从这些DEG中选择了10个具有高连接性的枢纽基因(,,,,,,,,,和)。
在KD中鉴定出几个新的枢纽基因,增强了我们对该疾病进展潜在分子机制的理解。这些基因可能是KD患者潜在的诊断生物标志物和/或治疗分子靶点。特别是整合素α-M(ITGAM)抑制剂可能是KD治疗的潜在靶点。